"increased bone turnover, especially skull and long bones (99m Tc MDP bone scan)"
"increased bone turnover, especially skull and long bones (99m Tc MDP bone scan)"
"increased haemopoietic activity (sulphur colloid scan)"
"KIT-activating KIT point mutation at codon 816 or in other critical regions of KIT in bone marrow or another extracutaneous organ"
"KIT-activating KIT point mutation at codon 816 or in other critical regions of KIT in bone marrow or another extracutaneous organ"
"KIT-activating KIT point mutation at codon 816 or in other critical regions of KIT in bone marrow or another extracutaneous organ"
"baseline serum tryptase concentration >20 ng/mL (in the case of an unrelated myeloid neoplasm, an elevated tryptase concentration does not count as an SM criterion); in the case of a known hereditary α-tryptasaemia (HαT), the tryptase level should be adjusted"
"Mastocytosis is a clonal disorder characterised by somatic mutations of the c-KIT proto-oncogene which encodes the receptor tyrosine kinase KIT (CD117) 15."
"Mastocytosis is a clonal disorder characterised by somatic mutations of the c-KIT proto-oncogene which encodes the receptor tyrosine kinase KIT (CD117) 15."
"Systemic mastocytosis with an associated haematological neoplasms (SM‐AHN): ~5% of cases of systemic mastocytosis are associated with myeloid malignancies:"
"Systemic mastocytosis with an associated haematological neoplasms (SM‐AHN): ~5% of cases of systemic mastocytosis are associated with myeloid malignancies:"
"mast cells in the bone marrow, blood, or another extracutaneous organ express one or more of the following: CD2, CD25, or CD30"
"B, high burden of disease (without organ dysfunction)"
Expected headings
"Associations"
"Skeletal, soft tissues"
"Abdominal"
"Pulmonary"
"CNS"
"baseline serum tryptase concentration >20 ng/mL (in the case of an unrelated myeloid neoplasm, an elevated tryptase concentration does not count as an SM criterion); in the case of a known hereditary α-tryptasaemia (HαT), the tryptase level should be adjusted"
"cutaneous mastocytosis, more common in children; adults with cutaneous manifestations usually have systemic disease 14"
"There is considerable heterogeneity in the presentation of mastocytosis, and in the rate of disease progression. Disease can be local and mild or systemic and life-threatening. Skin and bone marrow are most commonly affected. Clinical features include:"
"nausea, vomiting and diarrhoea"
"In systemic mastocytosis, abnormal proliferation and microscopic infiltration of mast cells variably involve the skin, bone marrow, gastrointestinal tract, lymph nodes, liver and spleen."
"effusions, pleural and pericardial"